Ribonuclease inhibitor (RI) is a large (~450 residues, ~49 kDa), acidic (pI ~4.7),
leucine-rich repeat proteinthat forms extremely tight complexes with certain ribonucleases. It is a major cellular protein, comprising ~0.1% of all cellular protein by weight, and appears to play an important role in regulating the lifetime of RNA.
RI has a surprisingly high
cysteinecontent (~6.5%, cf. 1.7% in typical proteins) and is sensitive to oxidation. RI is also rich in leucine(21.5%, compared to 9% in typical proteins) and commensurately lower in other hydrophobic residues, esp. valine, isoleucine, methionine, tyrosine, and phenylalanine.
RI is the classic leucine-rich repeat protein, consisting of alternating α-helices and β-strands along its backbone. These
secondary structureelements wrap around in a curved, right-handed solenoid that resembles a horseshoe. The parallel β-strands and α-helices form the inner and outer wall of the horseshoe, respectively. The structure appears to be stabilized by buried asparagines at the base of each turn, as it passes from α-helix to β-strand. The αβ repeats alternate between 28 and 29 residues in length, effectively forming a 57-residue unit that corresponds to its genetic structure (each exoncodes for a 57-residue unit).
Binding to ribonucleases
The affinity of RI for ribonucleases is perhaps the highest for any
protein-protein interaction; the dissociation constantof the RI-RNase A complex is roughly 20 fM under physiological conditions while that for the RI-angiogenin complex is even smaller (<1 fM). Remarkably, RI is able to bind a wide variety of RNases, despite having low sequence identity. Structural studies indicate that RNases bind like a "cork in the bottle", associating especially with the C-terminal end of RI; the interaction is largely electrostatic but also buries a lot of surface area (>25 nm2). Efforts to mutate RNases to lower their affinity for RI while maintaining their enzymatic activity have had limited success. However, mammalian RI seems unable to bind a few amphibian ribonucleases, such as onconase.
RI's affinity for ribonucleases is important, since ribonucleases have cytotoxic and cytostatic effects (especially against cancer cells), and are under investigation as potential cancer therapeutics. Successful evasion of the ubiquitous RI would be essential for the success of a ribonuclease drug, (since it would be ineffective bound to RI). The frog protein onconase is under investigation for treatment of skin cancers; unfortunately, the antigenicity of amphibian proteins makes them unsuitable for treating internal human cancers. Modifications of human ribonucleases that evade RI but retain their enzymatic activity have also been studied.
* Shapiro R. (2001) "Cytoplasmic Ribonuclease Inhibitor", "Methods Enzymol.", 341, 611-628.
* Kobe B and Deisenhofer J. (1993) "Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats", "Nature", "'366", 751-756.
* Kobe B and Deisenhofer J. (1995) "A structural basis of the interactions between leucine-rich repeats and protein ligands", "Nature", 374, 183-186.
* Kobe B and Deisenhofer J. (1996) "Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A" "J. Mol. Biol.", 264, 1028-1043.
* Papageorgiou AC, Shapiro R and Acharya KR. (1997) "Molecular recognition of human angiogenin by placental ribonuclease inhibitor - an X-ray crystallographic study at 2.0 Å resolution", "EMBO J.", 16, 5162-5177.
* Suzuki M, Saxena SK, Boix E, Prill RJ, Vasandani VM, Ladner JE, Sung C and Youle RJ. (1999) "Engineering receptor-rediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction", "Nature Biotech.", 17, 265-270.
* Shapiro R, Ruiz-Gutierrez M and Chen CZ. (2000) 'Analysis of the Interactions of Human Ribonuclease Inhibitor with Angiogenin and Ribonuclease A by Mutagenesis:Importance of Inhibitor Residues Inside versus Outside the C-terminal "Hot Spot"', "J. Mol. Biol.", 302, 497-519.
* Bretscher LE, Abel RL and Raines RT. (2000) "A Ribonuclease A Variant with Low Catalytic Activity but High Cytotoxicity", "J. Biol. Chem.", 275, 9893-9896.
Wikimedia Foundation. 2010.
Look at other dictionaries:
ribonuclease inhibitor — ribonuclease inhibitor. См. ингибитор рибонуклеазы. (Источник: «Англо русский толковый словарь генетических терминов». Арефьев В.А., Лисовенко Л.А., Москва: Изд во ВНИРО, 1995 г.) … Молекулярная биология и генетика. Толковый словарь.
Ribonuclease — Ribonuclease, abbreviated commonly as RNase, is a nuclease that catalyzes the degradation of RNA into smaller components. Ribonucleases can be divided into endoribonucleases and exoribonucleases, and comprise several sub classes within the EC 2.7 … Wikipedia
Enzyme inhibitor — Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme s activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and… … Wikipedia
Monoamine oxidase inhibitor — MAOI redirects here. For the Easter Island statues, see Moai. Monoamine oxidase Monoamine oxidase inhibitors (MAOIs) are a class of antidepressant drugs prescribed for the treatment of depression. They are particularly effective in treating… … Wikipedia
Phosphodiesterase inhibitor — A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), therefore preventing the inactivation of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and… … Wikipedia
Dihydrofolate reductase inhibitor — A dihydrofolate reductase inhibitor is a molecule that inhibits the function of dihydrofolate reductase, and is a type of antifolate. Since folate is needed by rapidly dividing cells to make thymine, this effect may be used to therapeutic… … Wikipedia
COX-2 inhibitor — COX 2 selective inhibitor is a form of non steroidal anti inflammatory drug (NSAID) that directly targets COX 2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX 2 reduces the risk of peptic ulceration, and is the… … Wikipedia
Acetylcholinesterase inhibitor — Acetylcholine … Wikipedia
Dihydropteroate synthase inhibitor — A dihydropteroate synthetase inhibitor is a drug that inhibits the action of dihydropteroate synthetase. Most are sulfonamides. Tetrahydrofolate synthesis pathway In bacteria, antibacterial sulfonamides act as competitive inhibitors of the enzyme … Wikipedia
Reverse-transcriptase inhibitor — Reverse transcriptase inhibitors (RTIs) are a class of antiretroviral drug used to treat HIV infection, tumors, and cancer. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase enzyme that retroviruses need to reproduce.… … Wikipedia